Apyx Medical Corp
Close on Oct 19, 2026
- Market cap
- $106.12M
- P/E (TTM)
- –
- Dividend yield
- –
About Apyx Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
Apyx Medical Corporation is an energy-based medical technology company focused on surgical aesthetics. The company operates through two main business segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its core offerings feature helium plasma technology marketed under the Renuvion and AYON Body Contouring System brand names for the cosmetic surgery market, as well as J-Plasma for hospital surgical procedures. These systems integrate electrosurgical generators and single-use handpieces to deliver precise thermal energy to tissue. The company also manufactures generators and components for other medical device makers under OEM contracts. In the United States, Apyx Medical sells directly to cosmetic surgeons, surgical centers, and medical offices, while utilizing distributor networks for international distribution.
The company manufactures products at facilities in Clearwater, Florida, and Sofia, Bulgaria, and operates a joint venture in China. As of late 2025, Apyx Medical employed 205 full-time personnel across its operations. The company maintains its corporate headquarters in Clearwater, Florida.
Summary of the business section of Apyx Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Apyx Medical Corp
- Founded
- 1982
- Headquarters
- Clearwater, FL
- Address
- 5115 Ulmerton Road 33760
- Phone
- (727) 384-2323
- Website
- apyxmedical.com
- Employees
- 205, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RSM US LLP, Tampa, Florida
Stock & identifiers
- Ticker
- APYX
- Exchange
- Nasdaq
- Shares outstanding
- 42M, Aug 5, 2026
- Public float
- $79.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 719135
- CUSIP
- 03837C106
- ISIN
- US03837C1062
- LEI
- 5299009QZVYUYO082S45
- EIN
- 11-2644611
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Charles D. Goodwin II | Chief Executive Officer, Director | 90,000 |
| Shawn David Roman | Chief Operating Officer | 15,000 |
| Moshe Citronowicz | Sr. V.P. of Operations | 493,504 |
| Matthew C. Hill | Chief Financial Officer | 8,500 |
| Lawrence Waldman | Director | 49,877 |
| Minnie Baylor-Henry | Director | – |
| Stavros G. Vizirgianakis | Director | 2,196,191 |
| Wendy Lauren Levine | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Charles D. Goodwin | $1.23M | $2.10M | $641.54K | $150 | – |
| FY2024 Charles D. Goodwin | $975.97K | $509.22K | $675.41K | $68 | – |
| FY2023 Charles D. Goodwin | $1.26M | $1.41M | $769.68K | $112 | – |
| FY2022 Charles D. Goodwin | $2.17M | -$653.64K | $974.61K | $18 | – |
| FY2021 Charles D. Goodwin | $1.59M | $3.15M | $776.13K | $178 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“At December 31, 2025, we had 205 full-time employees world-wide, of whom 4 were executive officers, 42 were supervisory personnel, 21 were sales personnel and 138 were technical support, administrative and production employees.”
Corporate history
Events identified from SEC filings